An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management
Open accessThe DOI matches its Crossref record; 324 of the 325 references it cites were found in a registry or an index.
Abstract
This document is an international evidence-based guideline on the diagnosis and management of idiopathic pulmonary fibrosis, and is a collaborative effort of the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, and the Latin American Thoracic Association. It represents the current state of knowledge regarding idiopathic pulmonary fibrosis (IPF), and contains sections on definition and epidemiology, risk factors, diagnosis, natural history, staging and prognosis, treatment, and monitoring disease course. For the diagnosis and treatment sections, pragmatic GRADE evidence-based methodology was applied in a question-based format. For each diagnosis and treatment question, the committee graded the quality of the evidence available (high, moderate, low, or very low), and made a recommendation (yes or no, strong or weak). Recommendations were based on majority vote. It is emphasized that clinicians must spend adequate time with patients to discuss patients' values and preferences and decide on the appropriate course of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, all patients originally gathered from hospital register using ICD-10 codes were meticulously re-assessed and re-classified using the year 2011 criteria, and the cases representing some other type of ILDs were excluded [14].”
From Comparison of disease progression subgroups in idiopathic pulmonary fibrosis (2019) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ILD still has a poor prognosis and the highest mortality rate during lung transplantation.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [48]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interstitial lung disease (ILD) remains an important indication for lung transplantation, and the number of patients with this disease is increasing.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [48]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), characterized histopathologically and/or radiologically with a usual interstitial pneumonia (UIP) pattern, is the most common adult form of interstitial pneumonia of unknown origin [1].”
From Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature (2014) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The median survival time for patients with IPF is 2 to 3 years from diagnosis and the 5-year survival rate ranges between 30% and 50% [1,5-7].”
From Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature (2014) · cites this paper as [1]
Experimental — accuracy not yet measured
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
ATS Statement: Guidelines for the Six-Minute Walk Test
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.166.1.at1102 · Cited by 11,195
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Interpretative strategies for lung function tests
Pellegrino, R., Viegi, G., Brusasco, V., Crapo, R. O., Burgos, F., Casaburi, R., Coates, A., van der Grinten, C. P. M., Gustafsson, P., Hankinson, J., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00035205 · Cited by 5,945
Fleischner Society: Glossary of Terms for Thoracic Imaging
Hansell, D. M., Bankier, A. A., MacMahon, H., McLoud, T. C., Müller, N. L., & Remy, J. (2008) · Radiology · doi:10.1148/radiol.2462070712 · Cited by 4,198
Self-citation(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Standardisation of the measurement of lung volumes
Wanger, J., Clausen, J. L., Coates, A., Pedersen, O. F., Brusasco, V., Burgos, F., Casaburi, R., Crapo, R., Enright, P., van der Grinten, C. P. M., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00035005 · Cited by 2,768
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Standardisation of the single-breath determination of carbon monoxide uptake in the lung
MacIntyre, N., Crapo, R. O., Viegi, G., Johnson, D. C., van der Grinten, C. P. M., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Enright, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034905 · Cited by 2,255
NOCTURNAL OXYGEN THERAPY TRIAL GROUP* (1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-3-391 · Cited by 2,218
Research works printed but not linked: 9
- Cochrane Handbook for Systematic Reviews of Interventions 5.0.2. Oxford: The Cochrane Collaboration, 2009. [online] 2009. [accessed 20 June 2010]; Available from: http://www.cochrane.org/resources/handbook/.
- Nadrous HF, Ryu JH, Douglas WW, Decker PA, Olson EJ. Impact of angiotensin-converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis. Chest 2004;126:438–446. [DOI] [PubMed] [Google Scholar]
- 2005, J Gastrointest Surg, 1053
- Marshall RP, Puddicombe A, Cookson WO, Laurent GJ. Adult familial cryptogenic fibrosing alveolitis in the UK. Thorax 2000;55:143–146. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001;345:517–525. [DOI] [PubMed] [Google Scholar]
- Kondo A, Saiki S. Acute exacerbation in idiopathic interstitial pneumonia (IIP). In: Harasawa M, Fukuchi Y, Morinari H, editors. Interstitial pneumonia of unknown etiology. Tokyo: University of Tokyo Press; 1989. pp. 33–42.
- Flaherty KR, Colby TV, Toews GB, Travis WD, Flint A, Gay SE, Strawderman RL III, Jain A, Lynch JP III, Martinez FJ. Differential presence of fibroblastic foci in UIP patients with or without conntective tissue disease. Am J Respir Crit Care Med 2001;163:A983. [Google Scholar]
- Molina-Molina M, Badia JR, Marin-Arguedas A, Xaubet A, Santos MJ, Nicolas JM, Ferrer M, Torres A. Outcomes and clinical characteristics of patients with pulmonary fibrosis and respiratory failure admitted to an intensive care unit: a study of 20 cases. Med Clin (Barc) 2003;121:63–67. [DOI] [PubMed] [Google Scholar]
- Pitsiou G, Ioannis Trigonis I, Tsiata E, Kontou P, Manolakoglou N, Stanopoulos I, Mavrofridis E, Argyropoulou P. Outcome of patients with pulmonary fibrosis admitted to the ICU for acute respiratory failure. Eur Respir J Suppl 2006;28:E650. [Google Scholar]
Cited by
Items 401–500 of 1,060
Rajala, K., Lehto, J. T., Sutinen, E., Kautiainen, H., Myllärniemi, M., & Saarto, T. H. (2017) · ERJ Open Research · doi:10.1183/23120541.00084-2017 · Cited by 148
Althobiani, M. A., Russell, A., Jacob, J., Ranjan, Y., Folarin, A., Hurst, J. R., & Porter, J. C. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1296890 · Cited by 148
Interstitial lung disease in anti-synthetase syndrome: Initial and follow-up CT findings
Debray, M., Borie, R., Revel, M., Naccache, J., Khalil, A., Toper, C., Israël‐Biet, D., Estellat, C., & Brillet, P. (2014) · European Journal of Radiology · doi:10.1016/j.ejrad.2014.11.026 · Cited by 148
An earlier and more confident diagnosis of idiopathic pulmonary fibrosis
du Bois, R. M. (2012) · European Respiratory Review · doi:10.1183/09059180.00000812 · Cited by 148
Blood Biomarkers in Idiopathic Pulmonary Fibrosis
Guiot, J., Moermans, C., Henket, M., Corhay, J.-L., & Louis, R. (2017) · Lung · doi:10.1007/s00408-017-9993-5 · Cited by 147
Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets
Liu, Y.-M., Nepali, K., & Liou, J.-P. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00935 · Cited by 147
Conti, S., Harari, S., Caminati, A., Zanobetti, A., Schwartz, J. D., Bertazzi, P. A., Cesana, G., & Madotto, F. (2018) · European Respiratory Journal · doi:10.1183/13993003.00397-2017 · Cited by 147
Ghebremariam, Y. T., Cooke, J. P., Gerhart, W., Griego, C., Brower, J., Doyle‐Eisele, M., Moeller, B. C., Zhou, Q., Ho, L. A., de Andrade, J. A., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0614-x · Cited by 147
Self-citationHuang, S. K., Scruggs, A. M., Donaghy, J., Horowitz, J. C., Zaslona, Z., Przybranowski, S., White, E. S., & Peters-Golden, M. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.146 · Cited by 147
Sverzellati, N., Lynch, D. A., Hansell, D. M., Johkoh, T., King, T. E., & Travis, W. D. (2015) · Radiographics · doi:10.1148/rg.2015140334 · Cited by 147
Self-citationGermline SFTPA1 mutation in familial idiopathic interstitial pneumonia and lung cancer
Nathan, N., Giraud, V., Picard, C., Nunes, H., Dastot-Le Moal, F., Copin, B., Galeron, L., De Ligniville, A., Kuziner, N., Reynaud-Gaubert, M., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw014 · Cited by 147
Shao, T., Shi, X., Yang, S., Zhang, W., Li, X., Shu, J., Alqalyoobi, S., Zeki, A. A., Leung, P. S. C., & Shuai, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.684699 · Cited by 147
Behr, J., Bendstrup, E., Crestani, B., Günther, A., Olschewski, H., Sköld, C. M., Wells, A., Wuyts, W., Koschel, D., Kreuter, M., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30044-3 · Cited by 146
Self-citationIdiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years
Raghu, G. (2017) · European Respiratory Journal · doi:10.1183/13993003.01209-2017 · Cited by 146
Self-citationAcute Exacerbation of Idiopathic Pulmonary Fibrosis: Outcome and Prognostic Factors
Simon-Blancal, V., Freynet, O., Nunes, H., Bouvry, D., Naggara, N., Brillet, P.-Y., Denis, D., Cohen, Y., Vincent, F., Valeyre, D., et al. (2012) · Respiration · doi:10.1159/000329891 · Cited by 146
Chartrand, S., Swigris, J. J., Stanchev, L., Lee, J. S., Brown, K. K., & Fischer, A. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.09.002 · Cited by 146
Self-citationInvolvement of PARK2-Mediated Mitophagy in Idiopathic Pulmonary Fibrosis Pathogenesis
Kobayashi, K., Araya, J., Minagawa, S., Hara, H., Saito, N., Kadota, T., Sato, N., Yoshida, M., Tsubouchi, K., Kurita, Y., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600265 · Cited by 145
Kim, H. J., Brown, M. S., Chong, D. Y., Gjertson, D. W., Lu, P., Kim, H. J., Coy, H., & Goldin, J. G. (2014) · Academic Radiology · doi:10.1016/j.acra.2014.08.004 · Cited by 145
Advances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
Liu, G. Y., Budinger, G. R. S., & Dematte, J. E. (2022) · BMJ · doi:10.1136/bmj-2021-066354 · Cited by 145
Labib, S., Williams, A., Yauk, C. L., Nikota, J. K., Wallin, H., Vogel, U. B., & Halappanavar, S. S. (2015) · Particle and Fibre Toxicology · doi:10.1186/s12989-016-0125-9 · Cited by 145
Sandner, P., & Stasch, J. P. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.08.022 · Cited by 145
Reversal of Myofibroblast Differentiation by Prostaglandin E2
Garrison, G. W., Huang, S. K., Okunishi, K., Scott, J. P., Penke, L. R. K., Scruggs, A. M., & Peters-Golden, M. L. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2012-0262oc · Cited by 145
Barba, T., Fort, R., Cottin, V., Provencher, S., Durieu, I., Mainbourg, S., Hot, A., Reynaud, Q., & Lega, J. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.07.013 · Cited by 145
CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab
Raghu, G., Martinez, F. J., Brown, K. K., Costabel, U., Cottin, V., Wells, A. U., Lancaster, L., Gibson, K. F., Haddad, T., Agarwal, P., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.01558-2014 · Cited by 144
Self-citationRaghu, G., Pellegrini, C. A., Yow, E., Flaherty, K. R., Meyer, K., Noth, I., Scholand, M. B., Cello, J., Ho, L. A., Pipavath, S., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30301-1 · Cited by 144
Self-citationEndoplasmic reticulum stress as a pro-fibrotic stimulus
Tanjore, H., Lawson, W. E., & Blackwell, T. S. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.11.011 · Cited by 144
Assayag, D., Elicker, B. M., Urbania, T. H., Colby, T. V., Kang, B. H., Ryu, J. H., King, T. E., Collard, H. R., Kim, D. S., & Lee, J. S. (2013) · Radiology · doi:10.1148/radiol.13130187 · Cited by 144
Self-citationThoracic Manifestations of Rheumatoid Arthritis
Esposito, A. J., Chu, S. G., Madan, R., Doyle, T. J., & Dellaripa, P. F. (2019) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2019.05.003 · Cited by 144
A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis
Lukey, P. T., Harrison, S. A., Yang, S., Man, Y., Holman, B. F., Rashidnasab, A., Azzopardi, G., Grayer, M., Simpson, J. K., Bareille, P., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01992-2018 · Cited by 143
Organ Fibrosis and Autoimmunity: The Role of Inflammation in TGFβ-Dependent EMT
Sisto, M., Ribatti, D., & Lisi, S. (2021) · Biomolecules · doi:10.3390/biom11020310 · Cited by 143
Idiopathic Pulmonary Fibrosis: Evolving Concepts
Ryu, J. H., Moua, T., Daniels, C. E., Hartman, T. E., Yi, E. S., Utz, J. P., & LIMPER, A. H. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.03.016 · Cited by 143
Self-citationHexokinase 2 couples glycolysis with the profibrotic actions of TGF-β
Yin, X., Choudhury, M., Kang, J. H., Schaefbauer, K. J., Jung, M.-Y., Andrianifahanana, M., Hernandez, D. M., & Leof, E. B. (2019) · Science Signaling · doi:10.1126/scisignal.aax4067 · Cited by 143
Mesenchymal Stem Cells and Idiopathic Pulmonary Fibrosis. Potential for Clinical Testing
Toonkel, R. L., Hare, J. M., Matthay, M. A., & Glassberg, M. K. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201207-1204pp · Cited by 143
Borie, R., Kannengiesser, C., Hirschi, S., Le Pavec, J., Mal, H., Bergot, E., Jouneau, S., Naccache, J.-M., Revy, P., Boutboul, D., et al. (2015) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2014.11.010 · Cited by 143
Self-citationPérez-Bogerd, S., Wuyts, W. A., Barbier, V., Demeyer, H., Muylem, A. V., Janssens, W., & Troosters, T. (2018) · Respiratory Research · doi:10.1186/s12931-018-0884-y · Cited by 143
Identification of the lipid biomarkers from plasma in idiopathic pulmonary fibrosis by Lipidomics
Yan, F., Wen, Z., Wang, R., Luo, W., Du, Y., Wang, W., & Chen, X. (2017) · BMC Pulmonary Medicine · doi:10.1186/s12890-017-0513-4 · Cited by 143
Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis
Huang, Y., Ma, S.-F., Espindola, M. S., Vij, R., Oldham, J. M., Huffnagle, G. B., Erb-Downward, J. R., Flaherty, K. R., Moore, B. B., White, E. S., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201607-1525oc · Cited by 142
Self-citationRole and New Insights of Pirfenidone in Fibrotic Diseases
Mora, D. A. L.-D. L., Sanchez-Roque, C., Montoya-Buelna, M., Sanchez-Enriquez, S., Lucano-Landeros, S., Macias-Barragan, J., & Armendariz-Borunda, J. (2015) · International Journal of Medical Sciences · doi:10.7150/ijms.11579 · Cited by 142
Lin, H., & Jiang, S. (2015) · PubMed Central · doi:10.3978/j.issn.2072-1439.2015.04.17 · Cited by 142
Therapeutic targets in idiopathic pulmonary fibrosis
Kolb, M. R. J., Bonella, F., & Wollin, L. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.07.062 · Cited by 142
Normativa sobre el diagnóstico y tratamiento de la fibrosis pulmonar idiopática
Xaubet, A., Ancochea, J., Bollo, E., Fernández‐Fabrellas, E., Franquet, T., Molina‐Molina, M., Montero, M. A., & Serrano‐Mollar, A. (2013) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2013.03.011 · Cited by 142
Self-citationJablonski, R. P., Kim, S., Cheresh, P., Williams, D. B., Morales‐Nebreda, L., Cheng, Y., Yeldandi, A., Bhorade, S., Pardo, A., Selman, M., et al. (2017) · The FASEB Journal · doi:10.1096/fj.201601077r · Cited by 142
Self-citationSafety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
Flaherty, K. R., Fell, C. D., Huggins, J. T., Nunes, H., Sussman, R., Valenzuela, C., Petzinger, U., Stauffer, J. L., Gilberg, F., Bengus, M., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.00230-2018 · Cited by 141
Self-citationCecchini, M. J., Hosein, K., Howlett, C. J., JOSEPH, M. G., & Mura, M. (2018) · Respiratory Research · doi:10.1186/s12931-018-0857-1 · Cited by 141
Clinical diagnosis of idiopathic pleuroparenchymal fibroelastosis: A retrospective multicenter study
Enomoto, Y., Nakamura, Y., Satake, Y., Sumikawa, H., Johkoh, T., Colby, T. V., Yasui, H., Hozumi, H., Karayama, M., Suzuki, Y., et al. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.11.003 · Cited by 141
Self-citationHamai, K., Iwamoto, H., Ishikawa, N., Horimasu, Y., Masuda, T., Miyamoto, S., Nakashima, T., Ohshimo, S., Fujitaka, K., Hamada, H., et al. (2016) · Disease Markers · doi:10.1155/2016/4759040 · Cited by 140
Idiopathic pulmonary fibrosis: Molecular mechanisms and potential treatment approaches
Glass, D. S., Grossfeld, D. J., Renna, H. A., Agarwala, P., Spiegler, P. A., Kasselman, L. J., Glass, A. D., DeLeon, J. R., & Reiss, A. B. (2020) · Respiratory Investigation · doi:10.1016/j.resinv.2020.04.002 · Cited by 140
Pulmonary Fibrosis in Hermansky–Pudlak Syndrome
Vicary, G. W., Vergne, Y., Santiago-Cornier, A., Young, L. R., & Roman, J. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201603-186fr · Cited by 140
Park, B., Park, H., Lee, S. M., Seo, J. B., & Kim, N. (2019) · Journal of Imaging Informatics in Medicine · doi:10.1007/s10278-019-00254-8 · Cited by 140
Organ, L. A., Duggan, A.-M. R., Oballa, E., Taggart, S. C., Simpson, J. K., Kang’ombe, A. R., Braybrooke, R., Molyneaux, P. L., North, B., Karkera, Y., et al. (2019) · Respiratory Research · doi:10.1186/s12931-019-1118-7 · Cited by 139
Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue
Caminati, A., Lonati, C., Cassandro, R., Elia, D., Pelosi, G., Torre, O., Zompatori, M., Uslenghi, E., & Harari, S. A. (2019) · European Respiratory Review · doi:10.1183/16000617.0044-2019 · Cited by 139
Genome-wide association analysis identifies six new loci associated with forced vital capacity
Loth, D. W., Artigas, M. S., Gharib, S. A., Wain, L. V., Franceschini, N., Koch, B., Pottinger, T. D., Smith, A. V., Duan, Q., Oldmeadow, C., et al. (2014) · Nature Genetics · doi:10.1038/ng.3011 · Cited by 138
Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis
Collard, H. R., Richeldi, L., Kim, D. S., Taniguchi, H., Tschoepe, I., Luisetti, M., Roman, J., Tino, G., Schlenker-Herceg, R., Hallmann, C., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.01339-2016 · Cited by 138
Self-citationCostabel, U., Bendstrup, E., Cottin, V., Dewint, P., Egan, J. J. J., Ferguson, J., Groves, R., Hellström, P. M., Kreuter, M., Maher, T. M., et al. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0112-1 · Cited by 138
Self-citationKusko, R. L., Brothers, J. F., Tedrow, J. R., Pandit, K. V., Huleihel, L., Perdomo, C., Liu, G., Juan-Guardela, B. M., Kass, D. J., Zhang, S., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201510-2026oc · Cited by 138
Physical Activity in Daily Life of Patients With Fibrotic Idiopathic Interstitial Pneumonia
Wallaert, B., Monge, E., Rouzic, O. L., Wémeau-Stervinou, L., Salleron, J., & Grosbois, J. (2013) · CHEST Journal · doi:10.1378/chest.13-0806 · Cited by 138
PD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders
Lee, D., Cho, M., Kim, E., Seo, Y., & Cha, J. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.09.026 · Cited by 137
The impact of emphysema in pulmonary fibrosis
Cottin, V. (2013) · European Respiratory Review · doi:10.1183/09059180.00000813 · Cited by 137
Humphries, S. M., Swigris, J. J., Brown, K. K., Strand, M. J., Gong, Q., Sundy, J. S., Raghu, G., Schwarz, M. I., Flaherty, K. R., Sood, R., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.01384-2018 · Cited by 137
Self-citationIdiopathic Pulmonary Fibrosis: Epidemiology, Natural History, Phenotypes
Sauleda, J., Núñez, B., Sala, E., & Soriano, J. B. (2018) · Medical Sciences · doi:10.3390/medsci6040110 · Cited by 137
Kaushik, S. S., Robertson, S. H., Freeman, M. S., He, M., Kelly, K. T., Roos, J. E., Rackley, C. R., Foster, W. M., McAdams, H. P., & Driehuys, B. (2015) · Magnetic Resonance in Medicine · doi:10.1002/mrm.25675 · Cited by 137
Progress in Understanding and Treating Idiopathic Pulmonary Fibrosis
Kropski, J. A., & Blackwell, T. S. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-041317-102715 · Cited by 137
Lee, T.-H., Yeh, C., Lee, Y.-T., Shih, Y.-C., Chen, Y.-T., Hung, C., You, M.-Y., Wu, P., Shentu, T., Huang, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18047-x · Cited by 137
Lung transplantation: indications and contraindications
Weill, D. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.06.141 · Cited by 137
Johannson, K. A., Balmes, J. R., & Collard, H. R. (2015) · CHEST Journal · doi:10.1378/chest.14-1299 · Cited by 137
Self-citationDisayabutr, S., Kim, E. K., Cha, S.-I., Green, G., Naikawadi, R. P., Jones, K. D., Golden, J. A., Schroeder, A., Matthay, M. A., Kukreja, J., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0158367 · Cited by 136
Self-citationTobacco Smoking and Risk for Pulmonary Fibrosis
Bellou, V., Belbasis, L., & Εvangelou, Ε. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.04.035 · Cited by 136
Salisbury, M. L., Lynch, D. A., van Beek, E. J. R., Kazerooni, E. A., Guo, J., Xia, M., Murray, S., Anstrom, K. J., Yow, E., Martinez, F. J., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201607-1385oc · Cited by 136
Self-citationReilkoff, R. A., Peng, H., Murray, L. A., Peng, X., Russell, T., Montgomery, R., Feghali-Bostwick, C., Shaw, A., Homer, R. J., Gulati, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201206-1109oc · Cited by 135
Cellular Senescence: Pathogenic Mechanisms in Lung Fibrosis
Parimon, T., Hohmann, M. S., & Yao, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126214 · Cited by 135
Japanese guideline for the treatment of idiopathic pulmonary fibrosis
Homma, S. A., Bando, M., Azuma, A., Sakamoto, S., Sugino, K., Ishii, Y., Izumi, S., Inase, N., Inoue, Y., Ebina, M., et al. (2018) · Respiratory Investigation · doi:10.1016/j.resinv.2018.03.003 · Cited by 135
Self-citationPD-1 hi CD8 + resident memory T cells balance immunity and fibrotic sequelae
Wang, Z., Wang, S., Goplen, N. P., Li, C., Cheon, I. S., Dai, Q., Huang, S., Shan, J., Ma, C., Ye, Z., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aaw1217 · Cited by 135
Makiguchi, T., Yamada, M., Yoshioka, Y., Sugiura, H., Koarai, A., Chiba, S., Fujino, N., Tojo, Y., Ota, C., Kubo, H., et al. (2016) · Respiratory Research · doi:10.1186/s12931-016-0427-3 · Cited by 135
Sharp, C., McCabe, M., Adamali, H. I., & Medford, A. R. L. (2016) · QJM · doi:10.1093/qjmed/hcw142 · Cited by 135
Rheumatoid Arthritis (RA) associated interstitial lung disease (ILD)
O’Dwyer, D. N., Armstrong, M. E., Cooke, G., Dodd, J. D., Veale, D. J., & Donnelly, S. C. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.07.004 · Cited by 135
Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
Collins, B. F., & Raghu, G. (2019) · European Respiratory Review · doi:10.1183/16000617.0022-2019 · Cited by 134
Self-citationAllen, R. J., Stockwell, A., Oldham, J. M., Guillén‐Guío, B., Schwartz, D. A., Maher, T. M., Flores, C., Noth, I., Yaspan, B. L., Jenkins, G. R., et al. (2022) · Thorax · doi:10.1136/thoraxjnl-2021-218577 · Cited by 134
NLRP3 participates in the regulation of EMT in bleomycin-induced pulmonary fibrosis
Tian, R., Zhu, Y., Yao, J., Meng, X., Wang, J., Xie, H., & Wang, R. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.05.028 · Cited by 134
Diagnostic Ability of a Dynamic Multidisciplinary Discussion in Interstitial Lung Diseases
Sadeleer, L. D., Meert, C., Yserbyt, J., Slabbynck, H., Verschakelen, J., Verbeken, E. K., Weynand, B., Langhe, E. D., Lenaerts, J. L., Nemery, B., et al. (2018) · CHEST Journal · doi:10.1016/j.chest.2018.03.026 · Cited by 134
Self-citationInoue, Y., Kaner, R. J., Guiot, J., Maher, T. M., Tomassetti, S., Moiseev, S., Kuwana, M., & Brown, K. K. (2020) · Chest · doi:10.1016/j.chest.2020.03.037 · Cited by 133
Self-citationLehtonen, S. T., Veijola, A., Karvonen, H., Lappi-Blanco, E., Sormunen, R., Korpela, S., Zagai, U., Sköld, M. C., & Kaarteenaho, R. (2016) · Respiratory Research · doi:10.1186/s12931-016-0328-5 · Cited by 133
Cho, S. J., Moon, J.-S., Lee, C.-M., Choi, A. M. K., & Stout-Delgado, H. W. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2016-0225oc · Cited by 133
Effects of nintedanib on the microvascular architecture in a lung fibrosis model
Ackermann, M., Kim, Y. O., Wagner, W. L., Schuppan, D., Valenzuela, C. D., Mentzer, S. J., Kreuz, S., Stiller, D., Wollin, L., & Konerding, M. A. (2017) · Angiogenesis · doi:10.1007/s10456-017-9543-z · Cited by 133
Wu, J., Song, D., Li, Z., Guo, B., Xiao, Y., Liu, W., Liang, L., Feng, C., Gao, T., Chen, Y., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0354-1 · Cited by 133
Araguás, E. T., Grau‐Junyent, J. M., Labirua-Iturburu, A., Hernández, F. J. G., Monteagudo-Jiménez, M., Fraile, G., Bujanda, L., Rodríguez‐Carballeira, M., Comet, L. S., & Selva-O’Callaghan, A. (2016) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2016.03.011 · Cited by 133
Lancaster, L., Albera, C., Bradford, W. Z., Costabel, U., du Bois, R. M., Fagan, E. A., Fishman, R. S., Glaspole, I., Glassberg, M. K., King, T. E., et al. (2016) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2015-000105 · Cited by 132
Self-citationBiomarkers in idiopathic pulmonary fibrosis
Drakopanagiotakis, F., Wujak, L., Wygrecka, M., & Markart, P. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.01.023 · Cited by 132
Living with idiopathic pulmonary fibrosis: an in-depth qualitative survey of European patients
Schoenheit, G., Becattelli, I., & Cohen, A. H. (2011) · Chronic Respiratory Disease · doi:10.1177/1479972311416382 · Cited by 132
Hoffmann, J., Wilhelm, J., Marsh, L. M., Ghanim, B., Klepetko, W., Kovács, G., Olschewski, H., Olschewski, A., & Kwapiszewska, G. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201401-0037oc · Cited by 132
Smoking and Idiopathic Pulmonary Fibrosis
Oh, C. K., Murray, L. A., & Molfino, N. A. (2012) · Pulmonary Medicine · doi:10.1155/2012/808260 · Cited by 132
Birring, S. S., Wijsenbeek, M. S., Agrawal, S., van den Berg, J. W., Stone, H., Maher, T. M., Tutuncu, A., & Morice, A. H. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30310-7 · Cited by 132
Short telomere length in IPF lung associates with fibrotic lesions and predicts survival
Snetselaar, R., van Batenburg, A. A., van Oosterhout, M. F. M., Kazemier, K. M., Roothaan, S. M., Peeters, T., van der Vis, J. J., Goldschmeding, R., Grutters, J. C., & van Moorsel, C. H. M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189467 · Cited by 131
Hu, M., Zhou, Q., Zheng, R., Li, X., Ling, J., Chen, Y., Jia, J., & Xie, C. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-01354-w · Cited by 131
Differential diagnosis of usual interstitial pneumonia: when is it truly idiopathic?
Wuyts, W. A., Cavazza, A., Rossi, G., Bonella, F., Sverzellati, N., & Spagnolo, P. (2014) · European Respiratory Review · doi:10.1183/09059180.00004914 · Cited by 131
Takemura, T., Akashi, T., Kamiya, H., Ikushima, S., Ando, T., Oritsu, M., Sawahata, M., & Ogura, T. (2012) · Histopathology · doi:10.1111/j.1365-2559.2012.04322.x · Cited by 130
Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation
Kreuter, M., Polke, M., Walsh, S. L. F., Krisam, J., Collard, H. R., Chaudhuri, N., Avdeev, S. N., Behr, J., Calligaro, G., Corte, T. J., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.01760-2019 · Cited by 130
Self-citationSturluson, Á., Huynh, M. T., Kaija, A. R., Laird, C., Yoon, S., Hou, F., Feng, Z., Wilmer, C. E., Colón, Y. J., Chung, Y. G., et al. (2019) · Molecular Simulation · doi:10.1080/08927022.2019.1648809 · Cited by 130
A lung targeted miR-29 mimic as a therapy for pulmonary fibrosis
Chioccioli, M., Roy, S., Newell, R., Pestano, L., Dickinson, B., Rigby, K., Herazo-Maya, J., Jenkins, G., Ian, S., Saini, G., et al. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.104304 · Cited by 129
A phase 2 randomized controlled study of tralokinumab in subjects with idiopathic pulmonary fibrosis
Parker, J. M., Glaspole, I. N., Lancaster, L. H., Haddad, T. J., She, D., Roseti, S. L., Fiening, J. P., Grant, E. P., Kell, C. M., & Flaherty, K. R. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201704-0784oc · Cited by 129
Self-citationPredisposition for Disrepair in the Aged Lung
Sueblinvong, V., Neujahr, D. C., Todd Mills, S., Roser-Page, S., Guidot, D., Rojas, M., Ritzenthaler, J. D., & Roman, J. (2012) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e318234c132 · Cited by 129
Metadata
- Authors
- Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., Lynch, D. A., Ryu, J. H., Swigris, J. J., Wells, A. U., Ancochea, J., Bouros, D., Carvalho, C., Costabel, U., Ebina, M., Hansell, D. M., Johkoh, T., Kim, D. S., King, T. E., Kondoh, Y., Myers, J., Müller, N. L., Nicholson, A. G., Richeldi, L., Selman, M., Dudden, R. F., Griss, B. S., Protzko, S. L., & Schünemann, H. J.
- Affiliations
- University of Washington (US)
- University of California, San Francisco (US)
- Mater Misericordiae University Hospital (IE)
- Ludwig-Maximilians-Universität München (DE)
- Mayo Clinic (US)
- University of Michigan (US)
- Tulane University (US)
- University of Colorado Boulder (US)
- National Jewish Health (US)
- Royal Brompton Hospital (GB)
- Hospital Universitario de La Princesa (ES)
- University Hospital of Alexandroupolis (GR)
- Universidade de São Paulo (BR)
- Tohoku University (JP)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- The University of Osaka (JP)
- University of Ulsan (KR)
- University of Modena and Reggio Emilia (IT)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- ORCID
- Raghu, Ganesh
- Collard, Harold R.
- Colby, Thomas V.
- Lasky, Joseph A.
- Lynch, David A.
- Ryu, Jay H.
- Swigris, Jeffrey J.
- Wells, Athol U.
- Ancochea, Julio
- Bouros, Demosthenes
- Carvalho, Carlos
- Costabel, Ulrich
- Johkoh, Takeshi
- King, Talmadge E.
- Kondoh, Yasuhiro
- Myers, Jeffrey
- Nicholson, Andrew G.
- Richeldi, Luca
- Selman, Moisés
- Schünemann, Holger J.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-03
- Volume
- 183
- Issue
- 6
- Pages
- 788-824
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- PMC
- PMC5450933
- OpenAlex
- W2167383172
- Cited by
- 7,186
- References
- 325
- Citations by year
- 2026: 187 · 2025: 307 · 2024: 436 · 2023: 432 · 2022: 522 · 2021: 640 · 2020: 607 · 2019: 596 · 2018: 607 · 2017: 605 · 2016: 569 · 2015: 531 · 2014: 426 · 2013: 370 · 2012: 256
- FWCI
- 304.18
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Funders
- National Heart, Lung, and Blood Institute (K23HL092227)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- idiopathic pulmonary fibrosis, diagnosis, management, natural history (disease), staging, prognosis, risk factors, treatment, disease surveillance, GRADE
- MeSH terms
- Europe, Humans, International Cooperation, Japan, Latin America, Societies, Medical, United States, Evidence-Based Medicine, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.